For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

Image courtesy of the U.S. Centers for Disease Control. Over the past 50 years, survival rates for a group of blood cancers known as myelodysplastic syndrome (MDS) have not improved, despite the ...

Personalized treatment strategies are increasingly important in managing lung cancer brain metastases, incorporating targeted therapies and immunotherapies. Stereotactic radiosurgery and whole-brain ...

Patterns of early and late recurrence across breast cancer subtypes in the CCTGMA.32 trial. Extended endocrine therapy after 5 years of adjuvant LHRH-agonist in premenopausal patients with ...